The world is still struggling with the coronavirus pandemic and a vaccine is much required at this point. Pfizer’s vaccine has gained approval from the United States Food and Drug Administration (FDA) and some other countries are also approving the vaccine but still, the recent days have been the days of some ups and downs for Pfizer when it comes to the Stock Market sector. The stocks of this company fell low on some days. This has brought up the question, whether or not one should go for purchasing the stocks of Pfizer.

Let us have a look at the latest statistical data of Pfizer Inc. and the company which is its partner in the Corona Virus vaccine, i.e., BioNTech SE – ADR:

Pfizer Inc. (NYSE: PFE)

  • Market Capital:  $228.561B
  • Average Volume:  39,455,182
  • 52 Week Range:  $26.45 – $43.08
  • Forward Dividend and Yield:  1.56 (3.79%)


  • Market Capital:  $30.652B
  • Average Volume:  3,634,690
  • 52 Week Range:  $27.73 – $131.00
  • Forward Dividend and Yield:  N/A (N/A)

Pfizer’s Effective Vaccine and other Reasons which make it a Buy Now Stock

The vaccine that these two firms have jointly developed against the coronavirus is 95% effective against this infection and is formulated by the new messenger RNA, i.e. mRNA technique. In the previous time, hardly any vaccines have received approvals that were formulated using this same technology but this vaccine from Pfizer has made its way.

The vaccine brought Pfizer into the limelight and since the past month when Pfizer made this announcement, there have been speculations and hopes all over the world regarding this vaccine but this is not all about Pfizer. During the year 2019, the breast cancer treatment drug of Pfizer also became the second best-selling drug of the company that year. Pfizer had signed a deal with Olema Pharmaceuticals (NASDAQ: OLMA) for the supply of this drug for further trials at the clinical level. This did not turn out to be as expected and two other studies demonstrated that the drug that was in combination was not so effective to clear the hurdles for its proper use.

Nevertheless, the company makes a good buy. When Pfizer announced about the vaccine, many other stocks dropped down and some stocks also rose. The stocks that saw a rise at that time were those which had suffered losses during the Covid-19 pandemic lockdown phase. This makes it clear that a vaccine would bring about a change and an investment in this company would not bear any losses to the investors. If we look at the company beyond that, even then the company is rising well and a company that rises steadily makes a good buy. After the stocks of this company went down, they have again seen a rise and did well in the market. Therefore, in the case of this firm, the occasional ups and downs have to be ignored because overall, the company is going to rise after the complete distribution of the vaccine begins.

Leave a Reply

Your email address will not be published.